Lilly Comfortable With Zyprexa's Second Place Detailing
This article was originally published in The Pink Sheet Daily
Executive Summary
Company notes it is second behind Johnson & Johnson's Risperdal. Reports that Zyprexa detailing has fallen off by 30% "could be overstated," Lilly says. Lilly is pleased with the current level of detailing for both Zyprexa and Cymbalta.
You may also be interested in...
Zyprexa May Be Helped By Study On Discontinuations Of Antipsychotics, Lilly Says
Study funded by NIH is examining all-cause treatment discontinuations for products in the class, with results expected to be published in the summer. Lilly hopes that results will highlight Zyprexa's efficacy and place side effects concerns in context.
Zyprexa May Be Helped By Study On Discontinuations Of Antipsychotics, Lilly Says
Study funded by NIH is examining all-cause treatment discontinuations for products in the class, with results expected to be published in the summer. Lilly hopes that results will highlight Zyprexa's efficacy and place side effects concerns in context.
Zyprexa, Zyrtec Medication Errors Prompt "Dear Doctor" Letter From Lilly
The letter, sent to 424,500 physicians and pharmacists, points to the similarity between product names and close proximity of storage as factors contributing to prescribing and dispensing errors. To prevent future errors, Lilly has changed labeling on bottles of 10 mg Zyprexa for "easier identification."